Prescribing Trends of Oral Anticoagulants in US Patients With Cirrhosis and Nonvalvular Atrial Fibrillation
Journal of the American Heart Association · 07.02.2023 · 12 (3)
DOI: 10.1161/jaha.122.026863 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 07.02.2023. Verfasst von Tracey G Simon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine, Brigham and Women's Hospital Harvard Medical School Boston MA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Kidney Failure, Chronic, Renal Insufficiency, Chronic, Stroke. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Background Many patients with cirrhosis have concurrent nonvalvular atrial fibrillation (NVAF). Data are lacking regarding recent oral anticoagulant (OAC) usage trends among US patients with cirrhosis and NVAF. Methods and Results Using MarketScan claims data (2012–2019), we identified patients with cirrhosis and NVAF eligible for OACs (CHA 2 DS 2 ‐VASc score ≥2 [men] or ≥3 [women]). We calculated the yearly proportion of patients prescribed a direct OAC (DOAC), warfarin, or no OAC. We stratified by high‐risk features (decompensated cirrhosis, thrombocytopenia, coagulopathy, chronic kidney disease, or end‐stage renal disease). Among 32 487 patients (mean age=71.6 years, 38.5% women, 15.1% with decompensated cirrhosis, mean CHA 2 DS 2 ‐VASc=4.2), 44.6% used OACs within 180 days of NVAF diagnosis, including DOACs (20.2%) or warfarin (24.4%). Compared with OAC nonusers, OAC users were less likely to have decompensated cirrhosis (18.6% versus 10.7%), thrombocytopenia (19.5% versus 12.5%), or chronic kidney disease/end‐stage renal disease (15.5% versus 14.0%). Between 2012 and 2019, warfarin use decreased by 21.0% (32.0% to 11.0%), whereas DOAC use increased by 30.6% (7.4% to 38.0%), and among all DOACs between 2012 and 2019, apixaban was the most commonly prescribed (46.1%). Warfarin use decreased and DOAC use increased in all subgroups, including in compensated and decompensated cirrhosis, thrombocytopenia, coagulopathy, chronic kidney disease/end‐stage renal disease, and across CHA 2 DS 2 ‐VASc categories. Among OAC users (2012–2019), DOAC use increased by 58.9% (18.7% to 77.6%). Among DOAC users, the greatest proportional increase was with apixaban (61.2%; P 55% of patients remain untreated, underscoring the need for clearer treatment guidance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine, Brigham and Women's Hospital Harvard Medical School Boston MA.
- Division of Gastroenterology and Hepatology Department of Medicine, Massachusetts General Hospital Harvard Medical School Boston MA.
- Division of General Internal Medicine Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston MA.
ORCID-Profile: Tracey G Simon, Sebastian Schneeweiss, Daniel E Singer, Sushama Kattinakere Sreedhara, Kueiyu Joshua Lin
Förderung
- NIDDK NIH HHS
- NIA NIH HHS
Zitieren
APA
Simon, T. G., Schneeweiss, S., Singer, D. E., Sreedhara, S. K., & Lin, K. J. (2023). Prescribing Trends of Oral Anticoagulants in US Patients With Cirrhosis and Nonvalvular Atrial Fibrillation. Journal of the American Heart Association, 12(3). https://doi.org/10.1161/jaha.122.026863
Vancouver
Simon TG, Schneeweiss S, Singer DE, Sreedhara SK, Lin KJ. Prescribing Trends of Oral Anticoagulants in US Patients With Cirrhosis and Nonvalvular Atrial Fibrillation. Journal of the American Heart Association. 2023;12(3). doi:10.1161/jaha.122.026863
BibTeX
@article{Simon2023,
author = {Simon, Tracey G and Schneeweiss, Sebastian and Singer, Daniel E and Sreedhara, Sushama Kattinakere and Lin, Kueiyu Joshua},
title = {Prescribing Trends of Oral Anticoagulants in US Patients With Cirrhosis and Nonvalvular Atrial Fibrillation},
journal = {Journal of the American Heart Association},
year = {2023},
volume = {12},
number = {3},
doi = {10.1161/jaha.122.026863}
}
EUVIMED